AVDL Stock Price | Avadel Pharmaceuticals PLC P/E, Revenue, EPS, & Forecasts

Avadel Pharmaceuticals PLC • AVDL

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Avadel Pharmaceuticals PLC

Ticker

AVDL

Trading on

NASDAQ

ISIN

IE00BDGMC594

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

CEO

Gregory J. Divis Jr.

Headquarters

10 Earlsfort Terrace, Dublin 2, undefined, Ireland, D02 T380

Employees

188

Website

avadel.com

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.

Metrics

BasicAdvanced

Market cap

$1.27B

P/E ratio

EPS

-$1.09

Dividend Yield

0.00%

Beta

1.63

Forward P/E ratio

36.5

EBIDTA

$-97.2M

Ex dividend date

Price & volume

Market cap

$1.27B

Average daily volume

1.2M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

36.5

PEG ratio

0.07

Trailing P/E

Price to sales

5.01

Price to book

11.48

Earnings

EPS

-$1.09

EPS estimate (current quarter)

-$0.16

EPS estimate (next quarter)

-$0.07

EBITDA

$-97.2M

Revenues (TTM)

$95.1M

Revenues per share (TTM)

$1.04

Technicals

Beta

1.63

52-week High

$19.09

52-week Low

$7.39

50-day moving average

$13.67

200-day moving average

$15.28

Short ratio

12.45

Short %

12.10%

Management effectiveness

ROE (TTM)

99.52%

ROA (TTM)

34.45%

Profit margin

111.64%

Gross profit margin

$16.6M

Operating margin

30.70%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

2,674.30%

Share stats

Outstanding Shares

96.3M

Float

83.2M

Insiders %

4.77%

Institutions %

80.00%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 10 analysts.

Average price target

$24.70

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.41

-$0.37

10.81%

Q3 • 23Beat

-$0.29

-$0.26

11.54%

Q4 • 23Beat

-$0.30

-$0.21

42.86%

Q1 • 24Beat

-$0.14

-$0.16

12.50%

Q2 • 24Beat

-$0.03

-$0.05

45.40%

Q3 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$50M

$-2.6M

5.25%

Q3 • 24

$50.4M

$-5M

10.00%

Q4 • 24

0.77%

92.11%

90.65%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$158M

$83.6M

52.82%

Q3 • 24

$164M

$90.4M

55.04%

Q4 • 24

3.78%

8.13%

4.19%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-6.9M

$4.9M

$1.2M

$-6.9M

Q3 • 24

$7.9M

$14.9M

$0.9M

$7.9M

Q4 • 24

214.27%

202.49%

25.23%

214.27%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Avadel Pharmaceuticals PLC share?

Avadel Pharmaceuticals PLC shares are currently traded for undefined per share.

How many shares does Avadel Pharmaceuticals PLC have?

Avadel Pharmaceuticals PLC currently has 96.3M shares.

Does Avadel Pharmaceuticals PLC pay dividends?

No, Avadel Pharmaceuticals PLC doesn't pay dividends.

What is Avadel Pharmaceuticals PLC 52 week high?

Avadel Pharmaceuticals PLC 52 week high is $19.09.

What is Avadel Pharmaceuticals PLC 52 week low?

Avadel Pharmaceuticals PLC 52 week low is $7.39.

What is the 200-day moving average of Avadel Pharmaceuticals PLC?

Avadel Pharmaceuticals PLC 200-day moving average is $15.28.

Who is Avadel Pharmaceuticals PLC CEO?

The CEO of Avadel Pharmaceuticals PLC is Gregory J. Divis Jr..

How many employees Avadel Pharmaceuticals PLC has?

Avadel Pharmaceuticals PLC has 188 employees.

What is the market cap of Avadel Pharmaceuticals PLC?

The market cap of Avadel Pharmaceuticals PLC is $1.27B.

What is the P/E of Avadel Pharmaceuticals PLC?

The current P/E of Avadel Pharmaceuticals PLC is null.

What is the EPS of Avadel Pharmaceuticals PLC?

The EPS of Avadel Pharmaceuticals PLC is -$1.09.

What is the PEG Ratio of Avadel Pharmaceuticals PLC?

The PEG Ratio of Avadel Pharmaceuticals PLC is 0.07.

What do analysts say about Avadel Pharmaceuticals PLC?

According to the analysts Avadel Pharmaceuticals PLC is considered a buy.